| 摘要: |
| ［摘要］ 抗体偶联药物（ADC）是一种很有潜力的新型靶向药物，具有抗体选择性强和药物活性高的优势。近年来，通过选择不同的靶点和小分子毒性物质，再加上连接方式的改进，有效的新型抗体偶联药物不断研发上市，代表着个体化精准治疗的快速发展。目前，全球范围内已有3种抗体偶联药物获批治疗乳腺癌，除用于人表皮生长因子受体2（HER2）阳性乳腺癌的曲妥珠单抗-美坦新偶联物（T-DM1）和曲妥珠单抗-德鲁替康（T-DXd,DS-8201）外，还有可使三阴性乳腺癌（TNBC）获益的戈沙妥珠单抗（SG,IMMU-132）。该文就近年来抗体偶联药物应用于乳腺癌治疗的国内外研究作一综述。 |
| 关键词: 抗体偶联药物 乳腺癌 研究进展 |
| DOI：10.3969/j.issn.1674-3806.2022.06.02 |
| 分类号:R 737.9 |
| 基金项目: |
|
| Recent advances in the application of antibody-drug conjugates in breast cancer |
|
ZENG Cheng, ZHANG Jian
|
|
Phase Ⅰ Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai 200032, China
|
| Abstract: |
| ［Abstract］ Antibody-drug conjugates(ADC) are a class of potential novel targeted drugs, with the advantages of strong selectivity of antibody and high activity of agents.In recent years,through the selection of different targets and small molecule toxic substances, coupled with the improvement of connection modes, effective ADC have been continuously developed and listed, indicating the rapid development of the personalized precision treatment. At present, three ADC have been approved for breast cancer worldwide. In addition to ado-trastuzumab emtansine(T-DM1) and trastuzumab deruxtecan(T-DXd, DS-8201) for the treatment of human epidermal growth factor receptor 2(HER2) positive breast cancer, there is also sacituzumab govitecan(SG, IMMU-132) which can benefit the patients with triple negative breast cancer(TNBC). This paper reviews the recent advances in the application of ADC for the treatment of breast cancer at home and abroad in recent years. |
| Key words: Antibody-drug conjugates(ADC) Breast cancer Recent advances |
